Literature DB >> 7490645

The incidence of primary central nervous system neoplasms before and after computerized tomography availability.

A Helseth1.   

Abstract

The observed incidence of primary intracranial neoplasms has increased dramatically among the elderly over the past several years. It is unclear to what extent this increase can be attributed to improved detection by new imaging technology and what portion might represent a true increase in incidence. The first computerized tomography (CT) scanner was operative in Norway in 1975 and became available in all geographical regions within 4 years. The author analyzed incidence data from the population-based Cancer Registry of Norway, placing particular emphasis on the basis for diagnosis (histological, imaging, or clinical findings) for the registrations. In the decade from 1983 to 1992, when the use of CT was widespread, incidence rates of primary intracranial neoplasms for individuals aged 55 to 74 and above 74 years were, respectively, 1.76 (95% confidence interval (CI), 1.63-1.90) and 3.35 (95% CI, 2.70-4.15) times the rates in 1963 to 1972 before CT was available. For persons older than 74 years, the relative incidence increase was 1.98-fold (95% CI, 1.53-2.56) for histologically verified tumors; 15.20 (95% CI, 7.80-29.61) when based on imaging (without histological evidence); and 3.33 (95% CI, 1.93-5.76) when based on clinical diagnosis (without imaging or histological evidence). In this age group, the increase for gliomas was 1.77 (95% CI, 1.18-2.65) and 2.28 (95% CI, 1.53-3.39) for meningioma patients. The present study demonstrates that new imaging technology has improved the diagnostic yield of primary intracranial neoplasms. For those older than 74 years, a large part of the three-fold incidence increase from the pre-CT decade 1963 to 1972 to the post-CT decade 1983 to 1992 can be attributed to improved tumor detection.

Entities:  

Mesh:

Year:  1995        PMID: 7490645     DOI: 10.3171/jns.1995.83.6.0999

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  7 in total

1.  Left temporal glioblastoma presenting with the involvement of selective memory: a case report.

Authors:  R Raffaele; I Vecchio; A Alvano; L Rampello
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

2.  Incidence of brain tumours in two English counties: a population based study.

Authors:  L H Pobereskin; J B Chadduck
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-10       Impact factor: 10.154

3.  Trend of brain tumor incidence by histological subtypes in Japan: estimation from the Brain Tumor Registry of Japan, 1973-1993.

Authors:  Satoshi Kaneko; Kazuhiro Nomura; Takesumi Yoshimura; Naohito Yamaguchi
Journal:  J Neurooncol       Date:  2002-10       Impact factor: 4.130

4.  Descriptive epidemiology of CNS tumors in France: results from the Gironde Registry for the period 2000-2007.

Authors:  I Baldi; A Gruber; A Alioum; E Berteaud; P Lebailly; A Huchet; T Tourdias; G Kantor; J P Maire; A Vital; H Loiseau
Journal:  Neuro Oncol       Date:  2011-10-06       Impact factor: 12.300

5.  Dysembryoplastic neuroepithelial tumors: nonspecific histological forms -- a study of 40 cases.

Authors:  C Daumas-Duport; P Varlet; S Bacha; F Beuvon; P Cervera-Pierot; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

6.  Incidence of and survival from oligodendroglioma in Denmark, 1943-2002.

Authors:  Malene Schjønning Nielsen; Helle Collatz Christensen; Michael Kosteljanetz; Christoffer Johansen
Journal:  Neuro Oncol       Date:  2008-12-09       Impact factor: 12.300

7.  Increasing incidence of central nervous system (CNS) tumors (2000-2012): findings from a population based registry in Gironde (France).

Authors:  Camille Pouchieu; Anne Gruber; Emilie Berteaud; Patrice Ménégon; Pascal Monteil; Aymeri Huchet; Jean-Rodolphe Vignes; Anne Vital; Hugues Loiseau; Isabelle Baldi
Journal:  BMC Cancer       Date:  2018-06-14       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.